Literature DB >> 25946030

Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: A Swedish Nationwide Study.

Daniel S Olsson1, Anna G Nilsson1, Ing-Liss Bryngelsson1, Penelope Trimpou1, Gudmundur Johannsson1, Eva Andersson1.   

Abstract

CONTEXT: Patients with hypopituitarism of various etiologies have excess mortality. The mortality in patients with nonfunctioning pituitary adenoma (NFPA), regardless of pituitary function, is less well studied.
OBJECTIVE: Our aim was to investigate mortality in patients with NFPA and to examine whether age at diagnosis, gender, tumor treatments, or hormonal deficiencies influence the outcome.
DESIGN: NFPA patients were identified and followed up in nationwide health registries in Sweden, 1987-2011. The criteria for identification were tested and validated in a subpopulation of the patients. SETTINGS: This was a nationwide, population-based study. PATIENTS: A total of 2795 unique patients with NFPA (1502 men, 1293 women) were identified and included in the study. Mean age at diagnosis was 58 years (men, 60 y; women, 56 y) and mean follow-up time was 7 years (range 0-25 y). INTERVENTION: There were no interventions. MAIN OUTCOME MEASURES: Standardized mortality ratios (SMRs) and annual incidence rates were calculated using the Swedish population as reference and presented with 95% confidence intervals.
RESULTS: Annual incidence of NFPA was 20.3 (18.8-21.9) cases per 1 million inhabitants. During the observation period, 473 patients died against an expected 431, resulting in an SMR of 1.10 (1.00-1.20). Patients diagnosed at younger than 40 years of age had an increased SMR of 2.68 (1.23-5.09). The SMR for patients with hypopituitarism (n = 1500) was 1.06 (0.94-1.19), and for patients with diabetes insipidus (n = 145), it was 1.71 (1.07-2.58). The SMR was increased in women with NFPA (1.29; 1.11-1.48) but not in men (1.00; 0.88-1.12). Women, but not men, with a diagnosis of hypopituitarism and/or diabetes insipidus also had an increased mortality ratio. SMRs due to cerebrovascular (1.73; 1.34-2.19) and infectious diseases (2.08; 1.17-3.44) were increased, whereas the SMR for malignant tumors was decreased (0.76; 0.61-0.94).
CONCLUSIONS: This nationwide study of patients with NFPA showed an overall excess mortality in women and in patients with a young age at diagnosis. Increased mortality was seen for cerebrovascular and infectious diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25946030     DOI: 10.1210/jc.2015-1475

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.

Authors:  P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

2.  Hypopituitarism-needs modern individualized treatment.

Authors:  Daniel S Olsson; Bengt-Åke Bengtsson
Journal:  Endocrine       Date:  2016-12-21       Impact factor: 3.633

Review 3.  Mortality in adults with hypopituitarism: a systematic review and meta-analysis.

Authors:  Sina Jasim; Fares Alahdab; Ahmed T Ahmed; Shrikant Tamhane; Larry J Prokop; Todd B Nippoldt; M Hassan Murad
Journal:  Endocrine       Date:  2016-11-05       Impact factor: 3.633

4.  Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism.

Authors:  Catharina Olivius; Kerstin Landin-Wilhelmsen; Daniel S Olsson; Gudmundur Johannsson; Åsa Tivesten
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

5.  Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  J Clin Med       Date:  2022-04-27       Impact factor: 4.964

6.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

Review 7.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

8.  ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centres.

Authors:  Michael W O'Reilly; Raoul C Reulen; Saket Gupta; Claire A Thompson; Rosemary Dineen; Eirena L Goulden; Gabriella Bugg; Harriet Pearce; Andy A Toogood; Neil J Gittoes; Rosalind Mitchell; Christopher J Thompson; John Ayuk
Journal:  Clin Endocrinol (Oxf)       Date:  2016-07-25       Impact factor: 3.478

Review 9.  Mortality in patients with non-functioning pituitary adenoma.

Authors:  Metaxia Tampourlou; Athanasios Fountas; Georgia Ntali; Niki Karavitaki
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

10.  Heart Rate Variability in Postoperative Patients with Nonfunctioning Pituitary Adenoma.

Authors:  Jeonghoon Ha; Hansang Baek; Chaiho Jeong; Minsoo Yeo; Seung-Hwan Lee; Jae Hyoung Cho; Ki-Hyun Baek; Moo Il Kang; Dong-Jun Lim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.